New Lung Cancer Drug Shows Promise at ASCO, Calls for Broader Trials
Ivonescimab, a lung cancer treatment from China, garnered attention at ASCO for its potential to extend survival in patients with squamous cell lung cancer, though experts urge for trials involving a more diverse patient base.
At the recent ASCO event, ivonescimab, a drug developed by Akeso and Summit, was highlighted for its ability to extend survival in patients with squamous cell lung cancer.
While the results are promising, medical professionals are advocating for follow-up studies that include a more diverse population to ensure the drug's efficacy across different demographics.
The development of ivonescimab marks a significant advancement in lung cancer treatment originating from China, but further research will be crucial in validating its benefits.